Biosensors   

Is Biosensors a good buy?

patent a product can be a waste of money if nobody wish to manufacture that product using that technology. for heart stent, there are other technology to be used. Only thing that can make this counter interesting is to get a ce mark and that mark enable biosenor to sell their product in the europe market. If you patent a product and cannot sell, you can consider that product a white elephant. 

 

folk, time to take profit and wait for another announcement on ce mark., this counter is too high now. I think this counter not supported by cpf, so trade with care.

 

biosensors patent approved in Europe. since its produce in-house, naturally all profits and licensing $$$ goes back to biosensors.

 

http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_A8E0F06EEED85F15482573330036CBF5/$file/European_Patent_Press_Release.pdf?openelement

 

 

Sold at $0.80... earned some kopi $$$... uncle old man liao... heart cant take it... cheong too fast, drop oso fast... later kena heart attack liao... take the kopi $$$ to drink to relak...

hopefully tmr morning another round

 

agreed with minesweeper..is never wrong to take profit.... when ur base is not low....

seriouly i was hoping they slowly inch up...rather then this type of cheong..... too fast for a old man like me..... later i need their stents

 

agreed... sigh, it's lunch time now... siao liao... very tense... hopefully the lunch wont cost me as expensive as 'lao han quan xi'  better safe then sorry...

 

frieend... in these market conditions better to make kopi$$$ whereever you can... market so valitile, never know whats gonna happen tomorrow....Bio has shown max jump today.. may not get this chance again.... better to sell and pocket profit as much we can...

 

Ok thanks... do u intend to keep or hit-and-run (today)? market still not stable... a bit scare scare leh... may be i should run away with kopi $$$

 

sorry bro...i dont know.... but some one in CNA forum have some dates there....but consume at own risk...... today play is more of china news..... hopeful we have more of such good news.....to push the price higher.....

 

do u know 'WHEN'?

 

hey bro...wait till the got the CE .....more to cumm....

 

I am just a small ikan bilis investor... not worth mentioning...

I read few reports on them last nite and decided to buy in today... they got patented from European. for more info, pls refer to POEMS or UOBKH research reports.

 

how much u vested in?

how come the share price suddenly shoot up, thought the announcement was yesterday?

 

Looks like on the uptrend...

vested... wish me luck

 

Hi Singaporegal....is that statment still valid after yesterday move?

 

This one's TA charts look bearish. I don't see any reversal in trend soon.

 

Just listened to the audio conference on the JW Medical Deal. 3 things were noted :

1)    When asked what will be the forward performance of JW Medical - Chua Kee Lock said that JW's 2007 results should be in line with the 80 % growth rate of the stent mkt in China

 

2)    When asked, if Biosensors will be doing any more deals, eg India - Chua Kee Lock said that they are always looking at the asia pacific region, where there is tremendous growth - I will interpret that India is one area for Biosensors to do M & A (kindly go and listen to the audio conference to verify this)

 

3)    When asked about the US$5 million payment by Terumo - Chua Kee Lock said that under confidentiality agrmnt with Terumo, they are unable to say anything - BUT it is an important milestone for Terumo, and similarly for Biosensors - My interpretation is that it ties up with the Terumo's annoucement abt their clinical trial starting in Japan. (ie the Japanese equivalent of the US IDE approval)

 

 

I wish to correct what Business Times Weekend Edition has wrongly reported under second row, second paragraph:

1. Biosensor's 50% holdings JWMS adds another US$5m of attributable earnings directly to Biosensor's full year results ended 31/03/2007 instead of JWMS earned US$5m for the year ended 31/03/2007 as reported.
2. JWMS has a net book value of US$11.4m as of 31/12/2006 instead of US$4.6m as reported.
3. JNJ's stent division is Cordis, not Gordis.

Biosensors plan to provide further profitablility guidance in Nov 2007. This is because profitability depends on commercialisation of Biomatrix (CE approval), plus part 2 of acquiring JWMS as wholly owned subsidiary and M&A in India. We all can see that in China, SFDA approved EXCEL in Jan 2006, JWMS started selling in Apr 2006, sold US$20m worth of EXCEL and made US$8.5m during that 9 months. DES business is very lucrative. Can you imagine the immediate huge profits rolling in when CE is approved? I feel the CEO is honest and meant what he said. I spoke to him several times this year, he said he wants Biosensors to be the most dominant player in Asia while waiting for CE and FDA approvals. I would say Biosensors is on the right track. Biosensors cannot wait and do nothing now but start conquering other key important emerging markets in Asia while waiting for CE and FDA. Don't forget Nobori (Biomatrix) already has IDE in Japan. To be fair to him, he has delivered what he said.

 

Like i said before, i have credible sources that Terumo's US$5m milestone payment is for NOBORI (BIOMATRIX) achieving IDE in Japan. Biosensors is bound by confidentiality clause to keep it silent unless Terumo makes the announcement on their own accord. Japan as we know is one of the most stringent regulatory authority for medical devices in the world. So that should say a lot about biosensor's technology. I seriously believe CE and IDE from FDA is very near.

Many other stent majors like BSX, MDT and ABT has little success penetrating into the lucrative and exponentially growing China market so buying 50% of JW adds on the attractiveness as an takeover target for MNCs that want immediate market penetration in the complex China market. EXCEL was approved in Jan 2006 and only started selling since Apr 2006. During this 9 months JW made US$8.5m. China market growing at 107% per annum plus EXCEL increasing its market share in China. Internally Biosensors projected profit for JW to be US$25m for 2007 but they kept it silent.

EXCEL is using sirolimus on biosensor's s-stent. Their biodegredable polymer is not PLA polymer but something similar to PLA polymer technology. I believe JW developed this technology with the help of Biosensors. There will be no infringement of JNJ's patent. In fact, Biosensors holds the patent of using any limus family drugs on biodegredable polymer for stent applications. In places like China, India, Pakistan, Latin America and many other 3rd world countries, IP rights are hard to enforce and Biosensor's strategy is to export EXCEL to these 3rd world countries. In China, EXCEL is selling about 40% cheaper than imported DES like Cypher and Taxus (heavy import tax). Plus China is a low cost manufacturing base. Biosensors have been managing JW's QC and full confidence in their product quality. With this distribution network in place, Biosensors can further penetrate Biomatrix into China when approvals are obtained. 

My friend's sources in Hong Kong told me that Biosensors is still negotiating with Weigao (H.K listed) to acquire the other 50% of JW that Weigao is currently holding. Biosensors have a upper hand now as they can jeopadise Medtronic/Weigao JV that was announced 5 months ago but still no progress. In fact, Biosensors will do something similar in India. We are right on track to become the DES leader in Asia.    

 

The buying over of 50 % JW Medical is probably a good move by Biosensors.

However, there are a few puzzling things that I do noy quite understand. JW's Excel stent uses the Biosensors's BARE metal stent(S-stent), their PLA polymer, BUT with the Sirolimus drug. (Drud used by J & J)

From the regulatory perspective, is JW Medical infringing on any patents ? - something similar to the Paclitaxel episode with Boston Scientific ?

2ndly, if the Excel stent continues to be popular, will it not cannibalise Biosensors' own Biomatirx, where Biolimus is used ? -Although in this case, you can say that financially, it does not matter, as long as Biosensors continue to sell both stents well.

3rdly, from the release of their financial results so far, there seems to be no indication that JW Medical is paying royalties for usage of the PLA technology, as well as for the purchase of the S-stent (Bare Metal stent), with which they make the Excel product with. I might be wrong on this - maybe, the revenue from this is incorporated into the sales of their bare metal stent.

While these are questions on my mind, the perspective for Biosensors seems to be getting brighter.

However, from the technical perspective, the negative trend is still there. For a first sign of trend reversal, normally the stock must sit on top of their 5 days ma (not a difficult thing to do). In fact, from observation, a distinct strong downtrend is often in place, when the stock cannot even clear and stay above its 5 days ma.

The stock also needs to see a clear 2-3 days strong 'up-days', preferably with strong vol. For confidence to be re-built in this stock, it needs to go above 0.70 cents, and preferably above 0.75.

Again, not an inducement to trade, caveat emptor.